1398-9995/asset/olbannerleft.gif?v=1&s=2207070238298c1b0c4b1e73fa97140fa65e5f81)
1398-9995/asset/olbannerright.gif?v=1&s=c902da976bf6db24fc36ec0480207615a3d14921)
Double-blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children
Article first published online: 28 APR 2007
DOI: 10.1111/j.1398-9995.1990.tb00947.x
1398-9995/asset/cover.gif?v=1&s=1b4cef9ea672c7adac9aec4870a5ad86dc5e55f6 "Allergy")
Additional Information
How to Cite
Piacentini, G. L., Sette, L., Peroni, D. G., Bonizzato, C., Bonetti, S. and Boner, A. L. (1990), Double-blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children. Allergy, 45: 612–616. doi: 10.1111/j.1398-9995.1990.tb00947.x
Publication History
- Issue published online: 28 APR 2007
- Article first published online: 28 APR 2007
- Accepted for publication 10, June, 1990
- Abstract
- References
- Cited By
Keywords:
- bronchial asthma: bronchial hypereactivity;
- flunisolide;
- hypothalamic-pituitary-adrenal function
A double-blind study was carried out in 20 asthmatic children in order to evaluate the therapeutic efficacy and safety of inhaled corticosteroid flunisolide. 0.5 mg of the drug was administered by a jet nebulizer twice daily for 2 months. Respiratory symptoms. pulmonary function values and methacholine PC2-FEV2 were evaluated, as also morning cortisol levels, plasma cortisol increase alter ACTH test, and 24-h urinary cortisol excretion. The data obtained show the efficacy of the drug in reducing symptoms. No significant difference was observed in pulmonary function values and in bronchial reactivity results between the two groups. No effect of flunisolide was observed on hypothalamic-pituitary-adrenal function. This study confirms the efficacy and safety of flunisolide (0.5 mg b.i.d.) in the treatment of asthmatic children.